Series C
$60m
Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform
US-Singapore biotech Allay Therapeutics has closed a $60 million Series C round led by Arboretum Ventures, with several healthcare investors taking part, to advance its long-acting post-surgical pain candidate into late-stage trials.